Abstract：
The diagnosis of myelodysplastic syndrome (MDS) is complex. Flow cytometric analysis of the myelomonocytic compartment can be helpful, but it is highly subjective and reproducibility by non-specialized groups is unclear. Analysis of the erythroid lineage by flow cytometry is emerging as potentially more reproducible and easier to conduct, while keeping a high diagnostic performance.
We review the evidence in this area, including 1) the use of well-established markers - CD71 and CD36 - and other less well-established markers and parameters; 2) the use of flow cytometric scores for the erythroid lineage; and 3) additional aspects, including the emergence of computational tools and the roles of flow cytometry beyond diagnosis. Finally, we discuss the limitations with the current evidence, including 1) the impact of the sample processing protocol and reagents on the results, 2) the lack of a standard gating strategy, and 3) conceptualization and design issues in the available publications.
We end by offering our recommendations for the current use - and our personal take on the value - of the analysis of erythroid lineage by flow cytometry.
We review the evidence in this area, including 1) the use of well-established markers - CD71 and CD36 - and other less well-established markers and parameters; 2) the use of flow cytometric scores for the erythroid lineage; and 3) additional aspects, including the emergence of computational tools and the roles of flow cytometry beyond diagnosis. Finally, we discuss the limitations with the current evidence, including 1) the impact of the sample processing protocol and reagents on the results, 2) the lack of a standard gating strategy, and 3) conceptualization and design issues in the available publications.
We end by offering our recommendations for the current use - and our personal take on the value - of the analysis of erythroid lineage by flow cytometry.
摘要：
■骨髓增生异常综合征（MDS）的诊断很复杂。骨髓单核细胞区室的流式细胞术分析可能是有帮助的，但它是高度主观的，非专门组的可重复性尚不清楚。通过流式细胞术对红系谱系的分析正在出现，因为它可能更具可重复性和更容易进行。同时保持高诊断性能。
■我们回顾了这方面的证据，包括1)使用公认的标志物-CD71和CD36-和其他不太公认的标志物和参数;2)使用红细胞谱系流式细胞术评分;3)其他方面,包括计算工具的出现和流式细胞术在诊断之外的作用.最后,我们讨论目前证据的局限性，包括1)样品处理方案和试剂对结果的影响，2）缺乏标准的门控策略，3）现有出版物中的概念化和设计问题。
■最后，我们通过流式细胞术对红细胞谱系分析提供了当前使用的建议-以及我们个人对价值的看法。
■我们回顾了这方面的证据，包括1)使用公认的标志物-CD71和CD36-和其他不太公认的标志物和参数;2)使用红细胞谱系流式细胞术评分;3)其他方面,包括计算工具的出现和流式细胞术在诊断之外的作用.最后,我们讨论目前证据的局限性，包括1)样品处理方案和试剂对结果的影响，2）缺乏标准的门控策略，3）现有出版物中的概念化和设计问题。
■最后，我们通过流式细胞术对红细胞谱系分析提供了当前使用的建议-以及我们个人对价值的看法。
